| Name | Title | Contact Details |
|---|
Your mobile strategy starts here. Gozio’s hospital wayfinding platform represents the next generation of mobile indoor wayfinding for your hospital system.
Lever builds modern recruiting software for teams to source, interview, and hire top talent. Our team strives to set a new bar for enterprise software with modern, well-designed, real-time apps. As the applicant tracking system of choice for Netflix, Eventbrite, Cirque Du SoleiI, ClearSlide, change.org, and thousands more leading companies, Lever means you hire the best by hiring together. Lever has raised $73 million in funding from Adam Street Partners, Scale Venture Partners, Matrix Partners, Y Combinator, Redpoint Ventures, Top Tier Capital Partners and Correlation Ventures among others. With an overall gender ratio of 50:50, Lever is also fiercely committed to building a team culture that celebrates diversity and inclusion.
Edge Communications - An innovative partner for Business Technology Services
We are a rag-tag crew of engineers, designers, visionaries, and artists. Together, we formed InterFocus INC with the intention of utilizing the latest social network and big data technologies to forever improve the online shopping experience.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.